Hainan Huluwa Pharmaceutical Group Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Hainan Huluwa Pharmaceutical Group's earnings have been declining at an average annual rate of -6.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 10.4% per year. Hainan Huluwa Pharmaceutical Group's return on equity is 9.9%, and it has net margins of 6.2%.
Belangrijke informatie
-6.2%
Groei van de winst
-8.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | 10.4% |
| Rendement op eigen vermogen | 9.9% |
| Nettomarge | 6.2% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Here's Why Hainan Huluwa Pharmaceutical Group (SHSE:605199) Has A Meaningful Debt Burden
Oct 23
Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Shares Climb 27% But Its Business Is Yet to Catch Up
Sep 25There's Reason For Concern Over Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Massive 27% Price Jump
Sep 25Risks To Shareholder Returns Are Elevated At These Prices For Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199)
Jun 07Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Shareholders Have More To Worry About Than Only Soft Earnings
May 03Opbrengsten en kosten
Hoe Hainan Huluwa Pharmaceutical Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 1,821 | 113 | 765 | 100 |
| 30 Jun 24 | 1,838 | 124 | 715 | 103 |
| 31 Mar 24 | 1,808 | 95 | 702 | 94 |
| 31 Dec 23 | 1,905 | 106 | 756 | 94 |
| 30 Sep 23 | 1,736 | 91 | 663 | 68 |
| 30 Jun 23 | 1,696 | 89 | 673 | 73 |
| 31 Mar 23 | 1,643 | 96 | 677 | 90 |
| 31 Dec 22 | 1,515 | 86 | 654 | 106 |
| 30 Sep 22 | 1,500 | 67 | 710 | 133 |
| 30 Jun 22 | 1,456 | 78 | 683 | 122 |
| 31 Mar 22 | 1,444 | 78 | 665 | 122 |
| 31 Dec 21 | 1,354 | 72 | 616 | 100 |
| 30 Sep 21 | 1,259 | 124 | 548 | 75 |
| 30 Jun 21 | 1,217 | 131 | 542 | 72 |
| 31 Mar 21 | 1,211 | 128 | 558 | 56 |
| 31 Dec 20 | 1,162 | 122 | 552 | 52 |
| 30 Sep 20 | 1,250 | 148 | 584 | 50 |
| 30 Jun 20 | 1,271 | 122 | 597 | 53 |
| 31 Mar 20 | 1,289 | 120 | 746 | 61 |
| 31 Dec 19 | 1,306 | 120 | 620 | 52 |
| 31 Dec 18 | 984 | 101 | 436 | 43 |
| 31 Dec 17 | 655 | 22 | 245 | 20 |
| 31 Dec 16 | 487 | 34 | 130 | 11 |
Kwaliteitswinsten: 605199 has a large one-off gain of CN¥42.4M impacting its last 12 months of financial results to 30th September, 2024.
Groeiende winstmarge: 605199's current net profit margins (6.2%) are higher than last year (5.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 605199's earnings have declined by 6.2% per year over the past 5 years.
Versnelling van de groei: 605199's earnings growth over the past year (23.6%) exceeds its 5-year average (-6.2% per year).
Winst versus industrie: 605199 earnings growth over the past year (23.6%) exceeded the Pharmaceuticals industry -1.2%.
Rendement op eigen vermogen
Hoge ROE: 605199's Return on Equity (9.9%) is considered low.